Cite
HARVARD Citation
Leiser, D. et al. (n.d.). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells. Molecular oncology. 9 (7), pp. 1434-1446. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Leiser, D. et al. (n.d.). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells. Molecular oncology. 9 (7), pp. 1434-1446. [Online].